Summit Therapeutics annual revenue
2018
2019
2020
2021
2022
2023
2024
2025
Summit Therapeutics Revenue Growth & History (SMMT)
Summit Therapeutics reported $0 in revenue for fiscal 2025.
View full Summit Therapeutics company overviewSummit Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | $0 | — |
| 2023 | 2023-12-31 | $0 | −$705,000 | −100.00% |
| 2022 | 2022-12-31 | $705,000 | −$1.1M | −61.03% |
| 2021 | 2021-12-31 | $1.8M | $949,000 | +110.35% |
| 2020 | 2020-12-31 | $860,000 | $117,000 | +15.75% |
| 2019 | 2019-12-31 | $743,000 | — | — |
| 2018 | 2019-01-31 | $57.1M | — | — |
Summit Therapeutics quarterly revenue
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q3.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | — | — |
| Q4 2025 | 2025-12-31 | $0 | — | — |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q4 2023 | 2023-12-31 | $0 | $0 | — |
| Q3 2023 | 2023-09-30 | $0 | −$220,000 | −100.00% |
| Q2 2023 | 2023-06-30 | $0 | −$235,000 | −100.00% |
| Q1 2023 | 2023-03-31 | $0 | −$250,000 | −100.00% |
| Q4 2022 | 2022-12-31 | $0 | −$251,000 | −100.00% |
| Q3 2022 | 2022-09-30 | $220,000 | −$1.1M | −83.19% |
| Q2 2022 | 2022-06-30 | $235,000 | $178,000 | +312.28% |
| Q1 2022 | 2022-03-31 | $250,000 | $58,000 | +30.21% |
| Q4 2021 | 2021-12-31 | $251,000 | $66,000 | +35.68% |
| Q3 2021 | 2021-09-30 | $1.3M | $1.1M | +623.20% |
| Q2 2021 | 2021-06-30 | $57,000 | −$113,000 | −66.47% |
| Q1 2021 | 2021-03-31 | $192,000 | −$132,000 | −40.74% |
| Q4 2020 | 2020-12-31 | $185,000 | — | — |
| Q3 2020 | 2020-09-30 | $181,000 | $33,000 | +22.30% |
| Q2 2020 | 2020-06-30 | $170,000 | — | — |
| Q1 2020 | 2020-03-31 | $324,000 | — | — |
| Q3 2019 · Sep 30 | 2019-09-30 | $148,000 | — | — |
Summit Therapeutics revenue growth trends
Summit Therapeutics's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Summit Therapeutics source filings ↗Community posts
AstraZeneca commits $2 billion to Summit alongside cancer-trial collaboration
AstraZeneca ($AZN) has agreed to invest $2 billion in Summit Therapeutics ($SMMT) through preferred shares convertible into common stock at an effective $18.36 per share. Approximately 108,955 preferred shares would each convert into 1,000 ...
